Substantial Variability Exists in International Consensus Definitions for Pediatric ALL Trial Outcomes
Researchers sought to address the variability in definitions for key outcomes in trials involving pediatric ALL.
Researchers sought to address the variability in definitions for key outcomes in trials involving pediatric ALL.
Researchers sought to determine the risk factors for patients with SCD developing a secondary neoplasm after undergoing HSCT.
Researchers sought to show an association between Charlson-Deyo Comorbidity Index and survival outcomes.
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
Researchers sought to determine whether vemurafenib retreatment would be effective in patients with relapsed or refractory hairy cell leukemia long-term.
Patients, caregivers scored higher on AML knowledge and perceived greater efficacy in communicating with oncologists.
Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.
Researchers sought to determine whether race, ethnicity, or BMI would have an impact on CAR-T therapy in patients with B-ALL.
Olverembatinib has demonstrated antitumor activity in patients with chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia.